Need help in rewriting this in my own words please

Company Information

GeoVax Labs is a clinical-stage biotechnology lab that specializes in immunotherapies

and vaccines against cancers and infectious diseases. According to their website, their vision and

strategy are "our business strategy is to advance our products through regulatory registration

while also seeking partnership or licensing arrangements that might otherwise maximize the

value to our shareholders. We also engage highly experienced third party resources/expertise

through collaborations and partnerships for preclinical and clinical testing with well-validated

industry, government, and other relevant entities" (GeoVax 2022).

The current products they offer include work in the research and development sector, and

in proprietary technology, and their current pipeline includes a substantial amount of vaccines:

Currently, GeoVax has a market share of 16.87 million. Compound annual growth rate

(CGAR) is the annual growth rate of an investment over a specified period longer than one year.

GeoVax's CAGR for the past three to five years is 14.48%, which tells us that GeoVax has a

good chance of attracting potential investors.

Exicure Inc is a clinical-stage biotechnology company that develops therapeutics for

immuno-oncology, genetic disorders, and other indications. Their vision and strategy include

"Exicure is focused on developing innovative medicines to treat diseases with a known genetic

basis. Our primary focus is on diseases that are amenable to our SNA technology with favorable

clinical development pathways and clear, unmet medical needs. We select potential therapeutic

candidates that leverage the key benefits of SNA platform with possible synergies across

indications and therapeutic targets." (Exicure, 2022).

They have a current pipeline of vaccinations and studies for various neurological

concerns, if you take a look at the chart below you can see where they are at with their currentdevelopments: